Indication
PAZONIB-200 is prescribed for treating advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma.

Pharmacology
– Pazopanib functions as a tyrosine kinase inhibitor, blocking specific proteins involved in cancer cell growth and spread. It targets receptors like VEGFR, PDGFR, and c-kit, thus hindering angiogenesis and tumor development.

Dosage and Administration
Typically, PAZONIB-200 is taken orally at a recommended dose of 800 mg once daily, regardless of food intake. It’s important to swallow the tablets whole with water and not adjust doses without medical consultation.

Interactions
Pazopanib may interact with various medications, particularly those metabolized by CYP3A4 enzymes and drugs affecting gastric pH. It’s crucial to disclose all medications, supplements, and herbal products to healthcare providers before starting treatment.

Side Effects
Common side effects of PAZONIB-200 include fatigue, diarrhea, hypertension, changes in hair color, nausea, vomiting, and appetite loss. Although rare, severe side effects such as liver toxicity, cardiac issues, and bleeding disorders may occur, warranting immediate medical attention.

Precautions and Warnings
Prior to initiating pazopanib treatment, patients should inform healthcare providers of any pre-existing medical conditions, especially liver or heart diseases. Regular monitoring of liver function, blood pressure, and cardiac health may be necessary. Additionally, the use of effective contraception is advised during treatment and for a period thereafter due to potential fetal harm.

Overdose Effects
Overdosing on PAZONIB-200 may lead to symptoms like severe fatigue, hypertension, and gastrointestinal disturbances. Management typically involves supportive care and symptomatic treatment, with urgent medical attention required if overdose is suspected.

This information serves as general knowledge and educational material only, and specific guidance should be sought from healthcare professionals or pharmacists based on individual circumstances.